Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration

ConclusionSwitching to brolucizumab in eyes refractory to aflibercept conferred favorable outcomes in controlling exudative changes. However, IOI and the regulation of the treatment interval to at least 8  weeks during the maintenance phase disrupted the continuation of brolucizumab treatment.
Source: Japanese Journal of Ophthalmology - Category: Opthalmology Source Type: research